Global Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report, By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational) and By Region, And Segment Forecasts, Till : 2030

Report ID : AMR1005050 | Industries : Healthcare | Published On :January 2024 | Page Count : 232

Global Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report, By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational) and By Region, And Segment Forecasts, Till – 2030

Market Overview

According to Analytical Market Research, the global Pulmonary Arterial Hypertension market estimated at USD 7.7 billion in 2022 and which expected, at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030. Key players in the Pulmonary Arterial Hypertension market employ various strategies to maintain and enhance their market presence. These strategies help key players capture a significant market share and remain competitive in the dynamic Pulmonary Arterial Hypertension market. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated includes proficient analysis, predictive analysis, prescriptive analysis, cumulative analysis, and value chain analysis.

PULMONARY ARTERIAL HYPERTENSION MARKET DYNAMICS: KEY DRIVERS & RESTRAINTS

Advances in Treatment Innovations
The pulmonary arterial hypertension (PAH) market is driven by continuous advancements in treatment innovations. Pharmaceutical companies are investing in research and development to introduce novel therapies and medications that improve the management of PAH. These innovations may include targeted therapies, combination treatments, and new drug delivery mechanisms, ultimately enhancing patient outcomes and expanding the market.
High Treatment Costs
A significant restraint in the pulmonary arterial hypertension market is the high costs associated with treatment. PAH therapies often involve specialized medications, diagnostic tests, and ongoing monitoring, leading to substantial financial burden on patients and healthcare systems. The high treatment costs can limit access to effective therapies and pose challenges for patients in both developed and developing regions. Cost considerations are a key restraint in achieving widespread adoption of PAH treatments.

How are Segments Performing in the Global Pulmonary Arterial Hypertension Market?

Pulmonary Arterial Hypertension Drug Class Segment Breakdown
According to Analytical Market Research, the Pulmonary Arterial Hypertension market by Drug Class is segmented into Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators.
Pulmonary Arterial Hypertension Type Segment Breakdown
According to Analytical Market Research, based on Route of Administration, the market is segmented into Branded, Generics.
Pulmonary Arterial Hypertension Route of Administration Segment Breakdown
According to Analytical Market Research, based on Type the market is segmented into Oral, Intravenous/ subcutaneous, Inhalational.
Pulmonary Arterial Hypertension Geographic Exploration
According to Analytical Market Research, the North America region is predicted to dominate the market, owing to the rise in the automotive industry in the region. Other regions competing in the market are North America, Europe, Middle East and Africa and Latin America respectively.

Noticeable Players Functioning in The Global Pulmonary Arterial Hypertension Market Include:

• United Therapeutics Corporation
• Bayer
• Gilead Sciences, Inc.
• Johnson & Johnson
• Viatris Inc.
• GlaxoSmithKline
• Sandoz Inc.
• Lupin Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries, Inc.
• Teva Pharmaceutical Industries Ltd.

KEY BREAKDOWN: Pulmonary Arterial Hypertension Market

By Drug Class:
• Endothelin Receptor Antagonists (ERAs)
• PDE-5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators
By Type:
• Branded
• Generics.
By Route of Administration:
• Oral
• Intravenous/ subcutaneous
• Inhalational
Geographical Exploration:
• North America
o The USA
o Canada
o Mexico
• Europe
o Germany
o France
o U.K.
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Middle East and Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest of Middle East & Africa

1. Research Methodology
1.1. Global Pulmonary Arterial Hypertension Market Snapshot, 2023 and 2030
1.2. Data Mining
1.3. Validation
1.4. Primary Interviews
1.5. List of Data Sources
1.6. Future Market Projections
1.7. Industry Developments and Key Market Events
2. Executive Summary
3. Market Overview
3.1. Market Scope and Definition
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunity
3.2.4. Challenges
3.2.5. Cumulative Impact due to Recent Energy Crisis
3.2.6. Cumulative Impact due to Nearing Economic Downturn
3.2.7. Post Covid-19 World Supply & Demand Conditions
3.2.8. Cumulative Impact of Russia-Ukraine Conflict
3.2.9. Key Trends
3.3. Pulmonary Arterial Hypertension Market: Value Chain
3.3.1. List of Raw Material Supplier
3.3.2. List of Manufacturers
3.3.3. List of Data Sources
3.4. Porter Five Force’s Analysis
3.5. Regulatory and Technology Landscape
4. Global Pulmonary Arterial Hypertension Market Outlook: Forecast (2023 – 2030)
4.1. Key Highlights
4.1.1. Market Size and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Current Market Size Forecast, 2023–2030
4.3. Global Pulmonary Arterial Hypertension Market Outlook: Drug Class
4.3.1. Introduction / Key Findings
4.3.2. Market Size (US$ Mn) and Forecast Drug Class, 2023 – 2030
4.3.2.1. Endothelin Receptor Antagonists (ERAs)
4.3.2.2. PDE-5 Inhibitors
4.3.2.3. Prostacyclin and Prostacyclin Analogs
4.3.2.4. SGC Stimulators
4.4. Global Pulmonary Arterial Hypertension Market Outlook: Type
4.4.1. Introduction / Key Findings
4.4.2. Market Size (US$ Mn) and Forecast By Type, 2023 – 2030
4.4.2.1. Branded
4.4.2.2. Generics
4.5. Global Pulmonary Arterial Hypertension Market Outlook: Route of Administration
4.5.1. Introduction / Key Findings
4.5.2. Market Size (US$ Mn) and Forecast By Route of Administration, 2023 – 2030
4.5.3. Oral
4.5.4. Intravenous/ subcutaneous
4.5.5. Inhalational
5. Global Pulmonary Arterial Hypertension Market Outlook: Region
5.1. Key Highlights
5.2. Market Size (US$ Mn) and Forecast By Region, 2023 – 2030
5.2.1. North America
5.2.2. Europe
5.2.3. Asia Pacific
5.2.4. Latin America
5.2.5. Middle East & Africa (MEA)
6. North America Pulmonary Arterial Hypertension Market Outlook: Forecast (2023 – 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2022
6.3.1. By Country
6.3.2. By Drug Class
6.3.3. By Type
6.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
6.4.1. U.S.
6.4.2. Canada
6.4.3. Mexico
6.5. Market Size (US$ Mn) and Forecast By Drug Class, 2023 – 2030
6.5.1. Endothelin Receptor Antagonists (ERAs)
6.5.2. PDE-5 Inhibitors
6.5.3. Prostacyclin and Prostacyclin Analogs
6.5.4. SGC Stimulators
6.6. Market Size (US$ Mn) and Forecast By Type, 2023 – 2030
6.6.1. Branded
6.6.2. Generics.
6.7. Market Size (US$ Mn) and Forecast By Route of Administration, 2023 – 2030
6.7.1. Oral
6.7.2. Intravenous/ subcutaneous
6.7.3. Inhalational
7. Europe Pulmonary Arterial Hypertension Market Outlook: Forecast (2023 – 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
7.3.1. By Country
7.3.2. By Drug Class
7.3.3. By Type
7.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
7.4.1. Germany
7.4.2. France
7.4.3. U.K.
7.4.4. Russia
7.4.5. Italy
7.4.6. Spain
7.4.7. Rest of Europe
7.5. Market Size (US$ Mn) and Forecast By Drug Class, 2023 – 2030
7.5.1. Endothelin Receptor Antagonists (ERAs)
7.5.2. PDE-5 Inhibitors
7.5.3. Prostacyclin and Prostacyclin Analogs
7.5.4. SGC Stimulators
7.6. Market Size (US$ Mn) and Forecast By Type, 2023 – 2030
7.6.1. Branded
7.6.2. Generics
7.7. Market Size (US$ Mn) and Forecast By Route of Administration, 2023 – 2030
7.7.1. Oral
7.7.2. Intravenous/ subcutaneous
7.7.3. Inhalational
8. Asia Pacific Pulmonary Arterial Hypertension Market Outlook: Forecast (2023 – 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Type
8.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. South Korea
8.4.5. Australia
8.4.6. New Zealand
8.4.7. Singapore
8.4.8. Malaysia
8.4.9. Rest of Asia
8.5. Market Size (US$ Mn) and Forecast By Drug Class, 2023 – 2030
8.5.1. Endothelin Receptor Antagonists (ERAs)
8.5.2. PDE-5 Inhibitors
8.5.3. Prostacyclin and Prostacyclin Analogs
8.5.4. SGC Stimulators
8.6. Market Size (US$ Mn) and Forecast By Type, 2023 – 2030
8.6.1. Branded
8.6.2. Generics
8.7. Market Size (US$ Mn) and Forecast By Route of Administration, 2023 – 2030
8.7.1. Oral
8.7.2. Intravenous/ subcutaneous
8.7.3. Inhalational
9. Latin America Pulmonary Arterial Hypertension Market Outlook: Forecast (2023 – 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Type
9.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Colombia
9.4.4. Peru
9.4.5. Chile
9.4.6. Venezuela
9.4.7. Rest of Latin America
9.5. Market Size (US$ Mn) and Forecast By Drug Class, 2023 – 2030
9.5.1. Endothelin Receptor Antagonists (ERAs)
9.5.2. PDE-5 Inhibitors
9.5.3. Prostacyclin and Prostacyclin Analogs
9.5.4. SGC Stimulators
9.6. Market Size (US$ Mn) and Forecast By Type, 2023 – 2030
9.6.1. Branded
9.6.2. Generics
9.7. Market Size (US$ Mn) and Forecast By Route of Administration, 2023 – 2030
9.7.1. Oral
9.7.2. Intravenous/ subcutaneous
9.7.3. Inhalational
10. Middle East & Africa Pulmonary Arterial Hypertension Market Outlook: Forecast (2023 – 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2023 – 2030
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Type
10.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
10.4.1. Saudi Arabia
10.4.2. UAE
10.4.3. Egypt
10.4.4. Kuwait
10.4.5. South Africa
10.4.6. Rest of Middle East & Africa
10.5. Market Size (US$ Mn) and Forecast By Drug Class, 2023 – 2030
10.5.1. Endothelin Receptor Antagonists (ERAs)
10.5.2. PDE-5 Inhibitors
10.5.3. Prostacyclin and Prostacyclin Analogs
10.5.4. SGC Stimulators
10.6. Market Size (US$ Mn) and Forecast By Type, 2023 – 2030
10.6.1. Branded
10.6.2. Generics
10.7. Market Size (US$ Mn) and Forecast By Route of Administration, 2023 – 2030
10.7.1. Oral
10.7.2. Intravenous/ subcutaneous
10.7.3. Inhalational
11. Competition Analysis
11.1. Market Share Analysis Of Top Vendors
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.2.3. Key Development Strategies
11.3. Company Profiles
11.3.1. Teva Pharmaceutical Industries Ltd
11.3.1.1. Overview
11.3.1.2. Offerings
11.3.1.3. Business Segment & Geographic Overview
11.3.1.4. Key Financials
11.3.1.5. Key Market Developments
11.3.1.6. Key Market Strategy
11.3.2. United Therapeutics Corporation
11.3.3. Bayer
11.3.4. Gilead Sciences, Inc.
11.3.5. Johnson & Johnson
11.3.6. Viatris Inc.
11.3.7. GlaxoSmithKline
11.3.8. Sandoz Inc.
11.3.9. Lupin Pharmaceuticals, Inc.
11.3.10. Sun Pharmaceutical Industries, Inc.